Combining PFA and LAA Closure in One Procedure: Findings From the COCONUT Study
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of EP Lab Digest or HMP Global, their employees, and affiliates.
EP LAB DIGEST. 2026;26(12).
Interview by Jodie Elrod
In this interview, Christian-Hendrik Heeger, MD, discusses the COCONUT study, a retrospective European registry of concomitant pulsed field ablation (PFA)–based pulmonary vein isolation and left atrial appendage closure (LAAC). He shares the study’s findings, practical lessons on appendage sizing and procedure sequence, and the need for prospective evidence before broader adoption.
Please introduce yourself and explain the clinical question that prompted the COCONUT study.
My name is Christian-Hendrik Heeger, and I am the director of the Department of Rhythmology at Asklepios Klinik Altona in Hamburg, Germany. My clinical and research interests focus on novel technologies and strategies for treating atrial fibrillation.
The aim of the COCONUT study was to analyze the safety, efficacy, and efficiency of a concomitant approach for catheter ablation—pulmonary vein isolation (PVI) via pulse field ablation (PFA) and left atrial appendage closure (LAAC). To date, this combined approach has been performed in only a limited account of cases, although patients with an indication for both procedures might benefit from a concomitant rather than sequential approach. The available data on this topic are currently limited to single-center case series and case reports.
Could you briefly summarize the study’s design and most important findings regarding the safety, efficacy, and efficiency of concomitant PFA-based PVI and LAAC?
The COCONUT study was a retrospective, European-wide registry study that included 155 patients treated at 22 centers in 9 European countries. All patients underwent PFA-based PVI using FARAPULSE (Boston Scientific) and LAAC via the WATCHMAN FLX device (Boston Scientific). The primary efficacy endpoint was successful PVI and LAAC, achieved in 97.4% of cases (100% for PVI and 97.4% for LAAC). The primary safety endpoint was severe periprocedural complications, which occurred in 1.9% of cases.
Which patients may benefit most from this “one-stop” approach to rhythm control and stroke prevention?
Patients with an indication for both PVI and LAAC will benefit from this one-stop approach. Based on the available data, a concomitant approach seems safe, effective, and efficient, eliminating the need to perform 2 separate procedures in the LA.
What procedural lessons emerged regarding single transseptal access, performing PVI before LAAC, and measuring the appendage before ablation?
In our experience, it is crucial to measure the LAA dimensions and determine device size before catheter ablation, using either TOE or computed tomography scan. In several cases, an edema of the LA ridge has been observed, which potentially could lead to a inaccurate LAA sizing. Additionally, it may be beneficial to perform PVI first, followed by LAAC, to prevent interaction between the ablation catheter and the LAAC device.
What are the key take-home messages, and what prospective evidence is still needed before this combined strategy can be adopted more broadly?
The key take-home messages are: (1) Concomitant PVI and LAAC seem safe, effective, and efficient; (2) LAA sizing should be performed before ablation; and (3) PVI should be performed first, followed by LAAC.
Our study reflects data from a retrospective cohort treated at highly experienced centers. This is a clear limitation. However, the COCONUT study is the largest dataset on this important topic to date. Prospective studies, including the ongoing COCONUT II study, will soon provide more data.
The transcripts were edited for clarity and length.



